Lisa Tofil, Partner with Holland & Knight LLP to Speak at The Knowledge Group’s The 340B Drug Pricing Program: Practical Tips to Ensure Compliance

New York, NY, January 10, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Lisa Tofil, Partner with Holland & Knight LLP will speak at The Knowledge Group’s webcast entitled: “The 340B Drug Pricing Program: Practical Tips to Ensure Compliance.” This event is scheduled for January 19, 2017 from 12:00pm – 2:00pm (ET).

For further details, please visit: https://www.theknowledgegroup.org/the-340b-drug-pricing-program-practical-tips-to-ensure-compliance-live-webcast/

About Lisa Tofil

Ms. Tofil represents a number of health care organizations, with significant expertise in hospital and health system financing, trauma centers and systems, air medical transport, emergency medical services and the 340B Drug Discount Program. She is an experienced advocate on numerous other healthcare issues and programs, including graduate medical education, biomedical research, transplantation, health resources issues, as well as public records and open meetings laws. Ms. Tofil works with clients on policy development, devising legislative and regulatory strategies, and intervening as necessary to draft and secure legislative or regulatory changes that advance client interests. In previous roles, she served as in house counsel to two large health systems, building their government relations functions and executing strategic government relations plans.

About Holland & Knight LLP

Holland & Knight is a global law firm with more than 1,200 lawyers and other professionals in 27 offices throughout the world. Our lawyers provide representation in litigation, business, real estate and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.

Abstract

Implementing an efficient and effective 340B Drug Pricing Program is an unnerving task. One of the challenges encountered by numerous covered entities when complying with the requirements of the 340B Program is the lack of clarity around the rules and regulations. The vagueness and complexity of rules can result in lost savings and an increased risk of noncompliance. In order to avoid such risks, it is necessary to develop policies and procedures that are in line with the framework of the 340B Program, maintain auditable records, conduct rigorous internal and external monitoring, and respond promptly to issues in the 340B compliance process.

In this live webcast, a seasoned panel of thought leaders and professionals assembled by The Knowledge Group will provide the audience with an in-depth analysis of the contextual and hot button compliance issues surrounding 340B. Speakers will also offer practical tips in navigating the complexity and the lack of clarity around issues like patient definition and duplicate discounts.

Key topics include:

- Overview of the 340B Drug Pricing Program
- Legislative and Regulatory Updates
- Covered Entity Eligibility and Patient Definition
- Significance of HRSA
- Contextual and Compliance Issues
- Contract Pharmacies
- Self-Reporting Noncompliance
- What’s Next for the 340B Program?

About The Knowledge Group/The Knowledge Congress Live Webcast Series

The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/